retatrutide patches ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide-Loaded Liposomes - CD Bioparticles

Tirzepatide is a dual agonist (GLP-1 + GIP) that achieved 20.9% over 72 weeks

Contact your GP or bariatric team if you experience: Recurrent episodes of suspected hypoglycaemia Confirmed blood glucose readings below 3.0 mmol/L on home monitoring Symptoms that significantly impact daily activities or quality of life Hypoglycaemic episodes occurring during fasting or overnight (suggesting alternative diagnoses) Difficulty managing symptoms with dietary modification alone Concerns about hypoglycaemia unawareness (lack of warning symptoms) Seek urgent medical attention (call 999 or attend A&E) if: Loss of consciousness or inability to swallow safely Seizure activity Severe confusion or altered mental state Persistent hypoglycaemia despite appropriate carbohydrate intake Injury sustained during a hypoglycaemic episode Patients should inform their GP and bariatric team about hypoglycaemic episodes, as this may warrant specialist endocrinology referral

Retatrutide addresses the root of that battle rather than adding more willpower to it

Phase 3 trials are currently ongoing and will provide data on longer treatment durations, maintenance protocols, and discontinuation outcomes specific to retatrutide

When performed thoughtfully, these treatments can help patients look refreshed and restednot overdone